PeptiDream
PeptiDream is a biopharmaceutical company founded in 2006 that specializes in the research and development of innovative pharmaceutical candidates. It utilizes its proprietary Peptide Discovery Platform System (PDPS) to create diverse non-standard peptide libraries, enabling the identification of potent and selective therapeutic candidates. The company focuses on developing constrained peptides, small molecules, and peptide-drug conjugates to address unmet medical needs and enhance patient quality of life. Through its advanced discovery platform, PeptiDream aims to position itself as a leader in the drug discovery and development sector.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
6 past transactions
Linqmed
Series B in 2025
Linqmed specializes in researching and developing radiopharmaceuticals for cancer treatment. It focuses on therapeutic and diagnostic drugs utilizing the radioisotope 64Cu.
Linqmed
Series B in 2025
Linqmed specializes in researching and developing radiopharmaceuticals for cancer treatment. It focuses on therapeutic and diagnostic drugs utilizing the radioisotope 64Cu.
Kleo
Series B in 2018
Kleo Pharmaceuticals, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2015. The company specializes in the development of immunotherapies that leverage small molecules to activate the body's immune system to combat cancer and infectious diseases. Kleo's innovative approach includes two primary types of compounds: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). These compounds are designed to emulate and enhance the effectiveness of biologics, offering advantages such as non-immunogenicity, high stability, lower molecular weight, and faster development times. By engaging the immune system to target cancer cells, Kleo aims to provide safer, more effective, and convenient treatment options, enabling healthcare providers to initiate cancer treatments swiftly and improve the likelihood of successful outcomes. As of January 2021, Kleo operates as a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Alivexis
Series A in 2018
Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.
PeptiStar
Corporate Round in 2018
Founded in Osaka, Japan in 2017, PeptiStar specializes in the development and manufacturing of peptide medicines. As a Contract Development and Manufacturing Organization (CDMO), it offers high-value services for traditional peptides to complex structures like macrocyclic and stapled peptides.
PharmaDesign
Acquisition in 2015
PharmaDesign is a genomic drug discovery venture company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.